Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) Return on Sales (2021 - 2025)

Coeptis Therapeutics Holdings has reported Return on Sales over the past 3 years, most recently at 1.88% for Q4 2025.

  • Quarterly results put Return on Sales at 1.88% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 9.01% (changed N/A YoY), and the annual figure for FY2025 was 9.01%, changed.
  • Return on Sales for Q4 2025 was 1.88% at Coeptis Therapeutics Holdings, up from 12.21% in the prior quarter.
  • Over the last five years, Return on Sales for COEPW hit a ceiling of 3.69% in Q2 2022 and a floor of 54.41% in Q1 2025.
  • Median Return on Sales over the past 3 years was 0.04% (2021), compared with a mean of 7.99%.
  • Peak annual rise in Return on Sales hit 360bps in 2022, while the deepest fall reached 307bps in 2022.
  • Coeptis Therapeutics Holdings' Return on Sales stood at 0.86% in 2021, then skyrocketed by 254bps to 3.05% in 2022, then tumbled by -162bps to 1.88% in 2025.
  • The last three reported values for Return on Sales were 1.88% (Q4 2025), 12.21% (Q3 2025), and 21.6% (Q2 2025) per Business Quant data.